Latest News and Press Releases

-- Advanced infectious disease vaccine programs with Sanofi Pasteur through initiation of COVID-19 clinical trial and publication of preclinical results; Influenza trial anticipated to begin mid-year...

-- First inhaled mRNA therapeutic delivered in multiple doses to the lungs of CF patients is generally safe and well tolerated; no observed pattern of increases in ppFEV1 -- -- Data supports...

-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- --...

LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...

LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...

-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –  -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial...

-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...

-- Announced interim results from single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis (CF) -- -- Received FDA clearance to advance 2nd program into clinical development,...

-- MRT5005 was generally well tolerated at low and mid-dose levels; no serious adverse events reported at any dose level -- -- Marked increases in ppFEV1 (percent predicted forced expiratory volume...